In this study, thirty-five N-substituted derivatives of cinnamic acid amide (cinnamamide) were evaluated for anti-Helicobacter pylori activity using an agar disc-diffusion method. Qualitative screening was performed on a reference H. pylori strain (ATCC 43504), resulting in the identification of the three most active compounds, 8 (R,S-(2E)-3-(4-chlorophenyl)-N-(2-hydroxypropyl)prop-2-enamide, minimal inhibitory concentration, MIC = 7.5 µg/mL), 23 ((2E)-3-(4-chlorophenyl)-N-(2-hydroxycyclohexyl)prop-2-enamide, MIC = 10 µg/mL), and 28 ((2E)-3-(4-chlorophenyl)-N-(4-oxocyclohexyl)prop-2-enamide, MIC = 10 µg/mL). These compounds were further tested on twelve well-characterized clinical strains, yielding MIC values that ranged from 10 to 1000 µg/mL. Preliminary safety assessments of the compounds were made using the MTT viability test for cytotoxicity and Ames test for mutagenicity, which showed them to be generally safe, although compounds 8 and 28 showed mutagenic activity at some of the tested concentrations. The results of this study showed the anti-H. pylori potential of cinnamamide derivatives.

中文翻译：

---

在参考菌株和临床细菌菌株上评估了选定的N-取代肉桂酰胺衍生物的抗幽门螺杆菌活性。

在这项研究中，使用琼脂圆盘扩散法评估了35种N-取代的肉桂酸酰胺（肉桂酰胺）衍生物的抗幽门螺杆菌活性。对参考幽门螺杆菌菌株（ATCC 43504）进行了定性筛选，从而鉴定出三种活性最高的化合物8（R，S-（2E）-3-（4-氯苯基）-N-（2-羟丙基）丙-2-烯酰胺，最小抑菌浓度，MIC = 7.5 µg / mL），23（（（2E）-3-（4-氯苯基）-N-（2-羟基环己基）丙-2-烯酰胺，MIC = 10 µg / mL）和28（（2E）-3-（4-氯苯基）-N-（4-氧代环己基）丙-2-烯酰胺，MIC = 10 µg / mL）。这些化合物在十二种特征明确的临床菌株上进行了进一步测试，得出的MIC值为10至1000 µg / mL。化合物的初步安全性评估是使用MTT细胞毒性的存活力测试和诱变的Ames测试进行的，这表明它们总体上是安全的，尽管化合物8和28在某些测试浓度下具有诱变活性。这项研究的结果显示了抗H。肉桂酰胺衍生物的幽门螺杆菌潜能。